1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 29 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2002Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantationMullighan, C.; Heatley, S.; Doherty, K.; Szabo, F.; Grigg, A.; Hughes, T.; Schwarer, A.; Szer, J.; Tait, B.; To, L.; Bardy, P.
2002High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceBranford, S.; Rudzki, Z.; Walsh, S.; Grigg, A.; Arthur, C.; Taylor, K.; Herrmann, R.; Lynch, K.; Hughes, T.
1997Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control.Hughes, T.; Grigg, A.; Szer, J.; Ho, J.; Ma, D.; Dale, B.; Green, R.; Norman, J.; Sage, R.; Herrmann, R.; Cannell, P.; Schwarer, A.; Taylor, K.; Atkinson, K.; Arthur, C.
2001Effect of down syndrome on the dimensions of dental crowns and tissuesBell, E.; Townsend, G.; Wilson, D.; Kieser, J.; Hughes, T.
2000Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimenCraddock, C.; Bardy, P.; Kreiter, S.; Johnston, R.; Apperley, J.; Marks, D.; Huber, C.; Kolbe, K.; Goulding, R.; Lawler, M.; Goldman, J.; Hughes, T.; Derigs, G.
2014Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cellsNievergall, E.; Ramshaw, H.; Yong, A.; Biondo, M.; Busfield, S.; Vairo, G.; Lopez, A.; Hughes, T.; White, D.; Hiwase, D.
2013Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLBranford, S.; Yeung, D.; Ross, D.; Prime, J.; Field, C.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Sullivan, B.; Briggs, N.; Hertzberg, M.; Seymour, J.; Reynolds, J.; Hughes, T.
2008Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiale Coutre, P.; Ottmann, O.; Giles, F.; Kim, D.; Cortes, J.; Gattermann, N.; Apperley, J.; Larson, R.; Abruzzese, E.; O'Brien, S.; Kuliczkowski, K.; Hochhaus, A.; Mahon, F.; Saglio, G.; Gobbi, M.; Kwong, Y.; Baccarani, M.; Hughes, T.; Martinelli, G.; Radich, J.; et al.
2013Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyRoss, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Yeung, D.; Dang, P.; Goyne, J.; Slader, C.; Filshie, R.; Mills, A.; Vaz de Melo, J.; White, D.; Grigg, A.; Hughes, T.
2013Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapyAngelini, S.; Soverini, S.; Ravegnini, G.; Barnett, M.; Turrini, E.; Thornquist, M.; Pane, F.; Hughes, T.; White, D.; Radich, J.; Kim, D.; Saglio, G.; Cilloni, D.; Iacobucci, I.; Perini, G.; Woodman, R.; Cantelli-Forti, G.; Baccarani, M.; Hrelia, P.; Martinelli, G.

Discover